96 related articles for article (PubMed ID: 10500835)
1. Aphidicolin markedly increases the in vitro sensitivity to ara-C of blast cells from patients with AML.
Sargent JM; Elgie AW; Williamson CJ; Taylor CG
Adv Exp Med Biol; 1999; 457():567-70. PubMed ID: 10500835
[TBL] [Abstract][Full Text] [Related]
2. Circumvention of ara-C resistance by aphidicolin in blast cells from patients with AML.
Sargent JM; Elgie AW; Williamson CJ; Lewandowicz GM; Taylor CG
Br J Cancer; 2001 Mar; 84(5):680-5. PubMed ID: 11237390
[TBL] [Abstract][Full Text] [Related]
3. Effects of CSFS and their combinations with chemotherapeutic agents (CH) on leukemic blasts (LB) in children (MTT-assay).
Litvinova E; Gurova K; Chimishkian K; Mentkevich G
Adv Exp Med Biol; 1999; 457():585-92. PubMed ID: 10500838
[TBL] [Abstract][Full Text] [Related]
4. In vitro cytotoxic drug activity and in vivo pharmacokinetics in childhood acute myeloid leukemia.
Lönnerholm G; Frost BM; Larsson R; Liliemark E; Nygren P; Peterson C
Adv Exp Med Biol; 1999; 457():429-35. PubMed ID: 10500819
[TBL] [Abstract][Full Text] [Related]
5. Aphidicolin decreases ex vivo resistance to cytosine arabinoside in childhood acute leukaemia.
Sargent JM; Williamson CJ; Hubeek I; Elgie AW; Taylor CG; Den Boer ML; Peters GJ; Kaspers GL
Oncol Rep; 2003; 10(6):2027-31. PubMed ID: 14534738
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of in vitro ara-C cytotoxicity by ribonucleotide reductase inhibitors, cyclin-dependent kinase modulators and the DNA repair inhibitor aphidicolin in paediatric acute myeloid leukaemia.
Hubeek I; Peters GJ; Broekhuizen AJ; Sargent J; Gibson BE; Creutzig U; Kaspers GJ
Br J Haematol; 2005 Oct; 131(2):219-22. PubMed ID: 16197453
[TBL] [Abstract][Full Text] [Related]
7. Aphidicolin markedly increases the platinum sensitivity of cells from primary ovarian tumours.
Sargent JM; Elgie AW; Williamson CJ; Taylor CG
Br J Cancer; 1996 Dec; 74(11):1730-3. PubMed ID: 8956785
[TBL] [Abstract][Full Text] [Related]
8. Effect of cytokines on the toxicity of cytostatic drugs on leukemic cells in vitro and in vivo.
Sundman-Engberg B; Tidefelt U; Paul C
Eur J Haematol; 1996; 56(1-2):1-6. PubMed ID: 8599980
[TBL] [Abstract][Full Text] [Related]
9. Regulation by retinoic acid and hydrocortisone of the anthracycline sensitivity of blast cells of acute myeloblastic leukemia.
Yang GS; Minden MD; McCulloch EA
Leukemia; 1994 Dec; 8(12):2065-75. PubMed ID: 7807996
[TBL] [Abstract][Full Text] [Related]
10. Comparison of BCL-2 and BAX protein expression with in vitro sensitivity to ARA-C and 6TG in AML.
Balkham SE; Sargent JM; Elgie AW; Williamson CJ; Taylor CG
Adv Exp Med Biol; 1999; 457():335-40. PubMed ID: 10500809
[TBL] [Abstract][Full Text] [Related]
11. Blast cell proliferative activity and sensitivity to GM-CSF in vitro are associated with early response to TAD-9 induction therapy in acute myeloid leukemia.
Jahns-Streubel G; Reuter C; Unterhalt M; Schleyer E; Wörmann B; Büchner T; Hiddemann W
Leukemia; 1995 Nov; 9(11):1857-63. PubMed ID: 7475275
[TBL] [Abstract][Full Text] [Related]
12. Hydrocortisone in culture protects the blast cells in acute myeloblastic leukemia from the lethal effects of cytosine arabinoside.
Yang GS; Wang C; Minkin S; Minden MD; McCulloch EA
J Cell Physiol; 1991 Jul; 148(1):60-7. PubMed ID: 1860896
[TBL] [Abstract][Full Text] [Related]
13. Evidence for the involvement of the glutathione pathway in drug resistance in AML.
Sargent JM; Williamson C; Hall AG; Elgie AW; Taylor CG
Adv Exp Med Biol; 1999; 457():205-9. PubMed ID: 10500795
[TBL] [Abstract][Full Text] [Related]
14. Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome: an explanation to differences in clinical outcome?
Frost BM; Gustafsson G; Larsson R; Nygren P; Lönnerholm G
Leukemia; 2000 May; 14(5):943-4. PubMed ID: 10803530
[No Abstract] [Full Text] [Related]
15. Induction of DNA ligase I by 1-beta-D-arabinosylcytosine and aphidicolin in MiaPaCa human pancreatic cancer cells.
Sun D; Urrabaz R; Buzello C; Nguyen M
Exp Cell Res; 2002 Oct; 280(1):90-6. PubMed ID: 12372342
[TBL] [Abstract][Full Text] [Related]
16. Topoisomerase II activities in AML and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines.
Gieseler F; Glasmacher A; Kämpfe D; Wandt H; Nuessler V; Valsamas S; Kunze J; Wilms K
Leukemia; 1996 Jul; 10(7):1177-80. PubMed ID: 8683999
[TBL] [Abstract][Full Text] [Related]
17. Comparison of P-glycoprotein expression and function with in vitro sensitivity to anthracyclines in AML.
Elgie AW; Sargent JM; Williamson CJ; Lewandowicz GM; Taylor CG
Adv Exp Med Biol; 1999; 457():29-33. PubMed ID: 10500777
[TBL] [Abstract][Full Text] [Related]
18. Generation of reactive oxygen intermediates after treatment of blasts of acute myeloblastic leukemia with cytosine arabinoside: role of bcl-2.
Hedley DW; McCulloch EA
Leukemia; 1996 Jul; 10(7):1143-9. PubMed ID: 8683994
[TBL] [Abstract][Full Text] [Related]
19. Augmentation by aphidicolin of 1-beta-D-arabinofuranosylcytosine-induced c-jun and NF-kappa B activation in a human myeloid leukemia cell line: correlation with apoptosis.
Kuwakado K; Kubota M; Bessho R; Kataoka A; Usami I; Lin YW; Okuda A; Wakazono Y
Leuk Res; 1995 Sep; 19(9):645-50. PubMed ID: 7564475
[TBL] [Abstract][Full Text] [Related]
20. Leukaemia cell drug resistance and prognostic factors in AML.
Nørgaard JM; Olesen G; Kristensen JS; Pedersen B; Hokland P
Eur J Haematol; 1999 Oct; 63(4):219-24. PubMed ID: 10530409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
